Dyslipidemia

Payal Kohli, MD, explores how evolving tools and strategies in lipid management are reshaping preventive cardiology.

Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.

VERVE-102 is targeting the reduction of LDL-C levels among individuals with hyperlipidemia and high lifetime cardiovascular risk.

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.

A recap of 10 clinical trials in cardiovascular care to know from the American College of Cardiology 2025 Scientific Sessions.

At ACC.25, Boer highlights treatment gaps in the US for lipid control in a high-risk ASCVD population.

At ACC.25, Robert S. Rosenson, MD, discusses the efficacy and safety of solbinsiran, an ANGPTL3 inhibitor, in a population with mixed dyslipidemia.

Steve Nissen, MD, discusses the phase 2 ALPACA trial and how it informs the potential of lepodisiran for lowering Lp(a).

Phase 2 data at ACC.25 provide further insight into the effects of lepodisiran on serum Lp(a) and other biomarkers of risk.

OAC-naive patients experienced a significantly smaller increase in stroke or systemic embolism with asundexian than apixaban.

First Procedure Performed at AHN Wexford Hospital, Demonstrating Network’s Ongoing Commitment to Bringing Complex Cardiovascular Care into the Community

The IND submission for VERVE-102 was supported by interim data from the dose-escalation portion of the ongoing Heart-2 Phase 1b clinical trial.

The approval expands the indication for vutrisiran, which becomes the first therapeutic approved by the FDA for the treatment of ATTR-CM.

Initiation of the MOMENTUM clinical trial will explore the prevalence of endogenous hypercortisolism in patients with resistant hypertension.

If approved, this indication targets the treatment of adult patients with heart failure with a left ventricular ejection fraction of ≥40%.

Food insecurity remained associated with incident CVD after adjustment for socioeconomic factors among participants in the 2000-2020 CARDIA study period.

The novel controlled metabolic accelerator significantly reduced fat-specific body weight but showed no improvements in exercise capacity over 19 weeks.

A study of 3 large US cohorts found a higher intake of butter was linked to greater mortality rates, while plant-based oil intake lowered total mortality.

The regulatory agency granted 510(k) clearance to Caristo Diagnostics' image analysis software to aid in coronary artery disease diagnosis.

Fonarow describes a revised classification of glucose levels that breaks down the normal range into lower and higher levels of associated cardiovascular risk.

Topline data from the pivotal Launch-HTN and Advance-HTN trials met primary endpoints, supporting lorundrostat for uncontrolled or resistant hypertension.

The regulatory agency accepted the BLA's filing and assigned a target action date of August 31, 2025.

The pivotal trial showed superior weight loss to placebo at 68 weeks but fell short of ≥25% weight loss initially expected by Novo Nordisk.

The agency approved the first generic of the anticoagulant rivaroxaban to lower the risk of cardiovascular and thromboembolic events in adults with CAD and PAD.